Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Syndax Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Syndax Pharmaceuticals, Inc.’s stock price such as:

• Syndax Pharmaceuticals, Inc.’s current stock price and volume
• Why Syndax Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for SNDX from analysts
• SNDX’s stock price momentum as measured by its relative strength

About Syndax Pharmaceuticals, Inc. (SNDX)

Before we jump into Syndax Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Want to learn more about Syndax Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Syndax Pharmaceuticals, Inc..

Syndax Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of June 18, 2026, 4:00 PM, CST, Syndax Pharmaceuticals, Inc.’s stock price was $19.000.

Syndax Pharmaceuticals, Inc. is 0% from its previous closing price of $19.000.

During the last market session, Syndax Pharmaceuticals, Inc.’s stock traded between $18.925 and $20.370. Currently, there are approximately 88.26 million shares outstanding for Syndax Pharmaceuticals, Inc..

Syndax Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Syndax Pharmaceuticals, Inc. Stock Price History

Syndax Pharmaceuticals, Inc.’s (SNDX) price is currently down 3.01% so far this month.

During the month of June, Syndax Pharmaceuticals, Inc.’s stock price has reached a high of $20.370 and a low of $16.660.

Over the last year, Syndax Pharmaceuticals, Inc. has hit prices as high as $25.590 and as low as $8.585. Year to date, Syndax Pharmaceuticals, Inc.’s stock is down 9.57%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Syndax Pharmaceuticals, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 18, 2026, there were 0 analysts who downgraded Syndax Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Syndax Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Syndax Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Syndax Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Syndax Pharmaceuticals, Inc. (SNDX) by visiting AAII Stock Evaluator.

Relative Price Strength of Syndax Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 18, 2026, Syndax Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 6.58%, which translates to a Momentum Score of 76 and is considered to be Strong.

Want to learn more about how Syndax Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Syndax Pharmaceuticals, Inc. Stock Price: Bottom Line

As of June 18, 2026, Syndax Pharmaceuticals, Inc.’s stock price is $19.000, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Syndax Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.